Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT04813406 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Anlotinib + Sintilimab

Sponsor

Henan Provincial People's Hospital